Rapid- and slow-acting insulins help control diabetes

Zablocki, Elaine
January 2006
Managed Healthcare Executive;Jan2006, Vol. 16 Issue 1, p46
Trade Publication
The article enlightens about the availability of two rapid-acting insulins with a more rapid onset and shorter duration of action than regular insulin to contain blood sugar levels in people with diabetes, whose population is increasing at an alarming rate in the United States. Byetta is a new medication for diabetes but has been included by few health plans in their formularies. Pharmaceutical companies, like Generex Biotechnology Corp. which has come up with an insulin spray, have been researching for user-friendly ways to supply insulin to the body. Lifestyle changes also remain important as a drug therapy. INSET: SOME INSULIN PRODUCTS..


Related Articles

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • First in Bananas and Noninjectable Insulin. Trecroci, D. // Diabetes Health;Jul2005, Vol. 14 Issue 7, p16 

    Reports on the approval of noninjectable insulin formulation from Generex Biotechnology in Ecuador. Estimated number of people with diabetes in the country; Implication of the decision according to the company.

  • European patents for Generex.  // European Pharmaceutical Executive;Sep2007, p9 

    The article reports that the European Patent Office has granted the fourth European patent of Generex Biotechnology Corp. entitled "Proteinic Drug Delivery System Using Membrane Mimetics." The patent includes formulation and process claims for liposome pharmaceutical formulation, which was...

  • life sciences In Brief.  // Chemical Market Reporter;3/21/2005, Vol. 267 Issue 12, p8 

    The article presents information on recent developments related to life sciences. Astralis Ltd. says that preliminary results from a Phase II study of its product candidate, a novel immuno-stimulatory product for psoriasis, did not meet its primary endpoint. Generex Biotechnology Corp. reports...

  • GENEREX EXPANDS PLAN FOR FDA IND FOR ORAL-LYN.  // Biotech Business;May2010, Vol. 23 Issue 5, p3 

    The article reports the move of Generex Biotechnology Corp. to include licensed and qualified nurse practitioners in plans for its U.S. Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for its oral insulin Generex Oral-lyn. Under the program,...

  • GENEREX REPORTS A NET LOSS OF $2.6 MILLION FOR THIRD QTR.  // Biotech Financial Reports;Aug2003, p1 

    Generex Biotechnology Corp. of Toronto, Ontario, a leader in the area of buccal drug delivery, has announced financial results for its third fiscal quarter ended April 30, 2003. The company reported a net loss for the quarter ended April 30, 2003 of $2.6 million, compared to a net loss of $3.2...

  • Noninjectable Insulins Win Approval: Pfizer in the US, Generex in South America. Koroneos, George // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p28 

    The article reports on the approval of noninjectable insulins in the United States and in South America. Pfizer's Exubera has been approved by the U.S. Food and Drug Administration to treat adults with type 1 and type 2 diabetes. Generex's oral insulin "Oral-lyn" went on the market in Ecuador...

  • New Inhalable Insulin Getting Ready for Clinical Trials.  // Diabetes Health;Sep2006, Vol. 15 Issue 9, p18 

    The article reports on the agreement of Generex Biotechnology Corp. with Cardinal Health Inc. to manufacture clinical trial batches of Generex Oral-Lyn inhalable insulin spray. The agreement is announced on June 22, 2006. Generex Oral-Lyn inhalable insulin spray is already available in Ecuador.

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics